About Fredun Pharmaceuticals Ltd
Data last updated: 08 January 2026
Fredun Pharmaceuticals Ltd is a public limited company based in Mumbai, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 08 June 1987, the company has been in operation for over 39 years.
Registered with ROC Mumbai under CIN U24239MH1987PLC043662. Listed on BSE: 539730.
Capital: an authorised share capital of ₹10 Cr and a paid-up capital of ₹5.37 Cr. Formerly known as Fredun Pharmaceuticals Private Limited. It is led by directors including Daisy Dsouza and Daulat Nariman Medhora.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2024. Office: Mumbai, Maharashtra.
As per the financials filed for FY 2025, the company reported a revenue of ₹456.27 Cr, a growth of 31% compared to the previous year.
The company has a workforce of approximately 388 employees as per the latest available data.
The company is associated with 1 brand - Fredun Group. As per MCA filings, the company has open charges of ₹245.38 Cr and satisfied charges of ₹136.27 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website fredungroup.com.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media**************
-
Registered Address11Th Floor Tower A Urmi Estate, 95 Ganpatrao Kadam Marg Lower Parel (W), Mumbai, Maharashtra, India – 400013
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd has one previous CIN (Corporate Identification Number): U24239MH1987PLC043662. The current CIN is L24239MH1987PLC043662, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24239MH1987PLC043662 | Current |
| U24239MH1987PLC043662 | Previous |
Associated Brands with Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd operates one associated brand: Fredun Group. These brands represent Fredun Pharmaceuticals Ltd's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Manufacturer of pharmaceutical formulations, APIs, and nutraceuticals | fredungroup.com |
Business Activity of Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd is audited by R.H.Nisar & Co. (ICAI peer reviewed, certificate valid till 2026-09-30) for the financial year 2026, as reported in its BSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| R.H.Nisar & Co. (ICAI peer reviewed, certificate valid till 2026-09-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd is currently managed by 7 directors, with 15 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Daisy Dsouza
Also directs:
Euro Panel Products Limited, Sanjana Cryogenic Storages Limited
|
Director | 24 Nov 2023 | 2 Years 7 Months | Current |
|
Daulat Nariman Medhora
Also directs:
Fredun Healthcare Private Limited, Fredun Retail Private Limited, Wagr Retail Private Limited and 2 more
|
Whole-Time Director | 08 Jun 1987 | 39 Years 1 Months | Current |
|
Fredun Nariman Medhora
Also directs:
Fredun Healthcare Private Limited, Fredun Retail Private Limited, Wagr Retail Private Limited and 5 more
|
Managing Director | 15 Sep 2006 | 19 Years 9 Months | Current |
| Anshu Gyan Agarwal | Additional Director | 30 Jul 2025 | 0 Years 11 Months | Current |
| Sonal Dharmin Desai | Additional Director | 30 Jul 2025 | 0 Years 11 Months | Current |
| Pooja Narendra Sanghavi | Additional Director | 28 Nov 2025 | 0 Years 7 Months | Current |
Financials of Fredun Pharmaceuticals Ltd FY 2026 filings available
Fredun Pharmaceuticals Ltd reported revenue of ₹633.33 Cr (up 40.21% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Revenue from Operations | ₹633.33 Cr | ₹451.71 Cr |
| Other Income | ₹5.8 Cr | ₹4.56 Cr |
| Total Income | ₹639.12 Cr | ₹456.27 Cr |
| Cost of Materials Consumed | ₹480.76 Cr | ₹323.98 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 |
| Changes in Inventories | -₹31.69 Cr | ₹6.05 Cr |
| Employee Benefit Expense | ₹32.94 Cr | ₹22.23 Cr |
| Finance Costs | ₹39.3 Cr | ₹22.38 Cr |
| Depreciation & Amortisation | ₹8.25 Cr | ₹5.04 Cr |
| Other Expenses | ₹62.57 Cr | ₹49.1 Cr |
| Total Expenses | ₹592.13 Cr | ₹428.78 Cr |
| Profit Before Exceptional Items & Tax | ₹47 Cr | ₹27.49 Cr |
| Exceptional Items | ₹0 | ₹0 |
| Profit Before Tax | ₹47 Cr | ₹27.49 Cr |
| Total Tax Expense | ₹14.38 Cr | ₹7.75 Cr |
| Net Profit | ₹32.62 Cr | ₹19.74 Cr |
| attributable to Owners | - | ₹0 |
| attributable to NCI | - | ₹19,000 |
| Other Comprehensive Income | ₹16.95 Lakh | -₹34.35 Lakh |
| Total Comprehensive Income | ₹32.79 Cr | ₹19.4 Cr |
| EBITDA (computed) | ₹94.54 Cr | ₹54.91 Cr |
| Basic EPS | ₹66.81 | ₹44.83 |
| Diluted EPS | ₹61.23 | ₹44.83 |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Total Assets | ₹642.08 Cr | ₹487.41 Cr |
| Non-current Assets | ₹143.91 Cr | ₹59.46 Cr |
| Current Assets | ₹498.17 Cr | ₹427.95 Cr |
| Property, Plant & Equipment | ₹117.63 Cr | ₹52.49 Cr |
| Inventories | ₹269.8 Cr | ₹239.89 Cr |
| Trade Receivables | ₹92.69 Cr | ₹177.12 Cr |
| Cash & Equivalents | ₹64.93 Cr | ₹63.69 Lakh |
| Equity (Net Worth) | ₹278.11 Cr | ₹141.38 Cr |
| Equity Share Capital | ₹5.47 Cr | ₹4.72 Cr |
| Borrowings (Non-current) | ₹56.31 Cr | ₹16.53 Cr |
| Borrowings (Current) | ₹166.09 Cr | ₹150.61 Cr |
| Total Debt (computed) | ₹222.4 Cr | ₹167.15 Cr |
| Current Liabilities | ₹296.86 Cr | ₹321.18 Cr |
| Total Liabilities | ₹363.97 Cr | ₹346.03 Cr |
| Metrics | FY 2026 | FY 2025 |
|---|---|---|
| Operating Cash Flow | ₹26.28 Cr | -₹29.06 Cr |
| Investing Cash Flow | -₹73.59 Cr | -₹6.35 Cr |
| Financing Cash Flow | ₹121.45 Cr | ₹39.12 Cr |
| Capital Expenditure | ₹73.59 Cr | ₹6.11 Cr |
| Free Cash Flow (computed) | -₹47.31 Cr | -₹35.17 Cr |
| Dividends Paid | ₹0 | ₹0 |
| Net Change in Cash | ₹74.13 Cr | ₹3.7 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 |
|---|---|---|---|---|---|
| Revenue from Operations | ₹210.41 Cr | ₹159.93 Cr | ₹143.59 Cr | ₹119.4 Cr | ₹165.44 Cr |
| Other Income | ₹2.64 Cr | ₹99.7 Lakh | ₹1.71 Cr | ₹45.21 Lakh | ₹1.97 Cr |
| Total Income | ₹213.06 Cr | ₹160.92 Cr | ₹145.29 Cr | ₹119.86 Cr | ₹167.41 Cr |
| Cost of Materials Consumed | ₹173.54 Cr | ₹118.91 Cr | ₹100.44 Cr | ₹91.08 Cr | ₹125.01 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹22.09 Cr | -₹7.35 Cr | ₹4.41 Cr | -₹6.66 Cr | -₹1.23 Cr |
| Employee Benefit Expense | ₹8.86 Cr | ₹8.15 Cr | ₹8.3 Cr | ₹7.63 Cr | ₹9.7 Cr |
| Finance Costs | ₹14.49 Cr | ₹10.55 Cr | ₹7.73 Cr | ₹6.53 Cr | ₹8.15 Cr |
| Depreciation & Amortisation | ₹3.15 Cr | ₹1.78 Cr | ₹1.89 Cr | ₹1.42 Cr | ₹1.84 Cr |
| Other Expenses | ₹23.86 Cr | ₹14.88 Cr | ₹9.81 Cr | ₹10.81 Cr | ₹16.68 Cr |
| Total Expenses | ₹201.81 Cr | ₹146.92 Cr | ₹132.59 Cr | ₹110.81 Cr | ₹160.14 Cr |
| Profit Before Exceptional Items & Tax | ₹11.25 Cr | ₹14 Cr | ₹12.71 Cr | ₹9.04 Cr | ₹7.26 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹11.25 Cr | ₹14 Cr | ₹12.71 Cr | ₹9.04 Cr | ₹7.26 Cr |
| Total Tax Expense | ₹46.81 Lakh | ₹3.52 Cr | ₹3.27 Cr | ₹2.27 Cr | ₹1.26 Cr |
| Net Profit | ₹10.78 Cr | ₹10.48 Cr | ₹9.43 Cr | ₹6.77 Cr | ₹6 Cr |
| attributable to Owners | - | ₹0 | ₹0 | ₹0 | ₹0 |
| attributable to NCI | - | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹16.55 Lakh | ₹0 | ₹0 | ₹0 | -₹34.35 Lakh |
| Total Comprehensive Income | ₹10.95 Cr | ₹10.48 Cr | ₹9.43 Cr | ₹6.77 Cr | ₹5.66 Cr |
| EBITDA (computed) | ₹28.88 Cr | ₹26.34 Cr | ₹22.33 Cr | ₹16.99 Cr | ₹17.25 Cr |
| Basic EPS | ₹19.70 | ₹19.53 | ₹19.98 | ₹14.33 | ₹12.71 |
| Diluted EPS | ₹18.22 | ₹17.71 | ₹19.98 | ₹14.33 | ₹12.71 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹633.33 Cr | ₹451.71 Cr | ₹346.58 Cr | ₹274.34 Cr | ₹221.74 Cr | ₹131.55 Cr | ₹110.3 Cr | ₹95.41 Cr |
| Other Income | ₹5.8 Cr | ₹4.56 Cr | ₹2.49 Cr | ₹2.16 Cr | ₹4.35 Cr | ₹3.74 Cr | ₹2.99 Cr | ₹2 Cr |
| Total Income | ₹639.12 Cr | ₹456.27 Cr | ₹349.07 Cr | ₹276.5 Cr | ₹226.09 Cr | ₹135.29 Cr | ₹113.29 Cr | ₹97.4 Cr |
| Cost of Materials Consumed | ₹480.76 Cr | ₹323.98 Cr | ₹282.42 Cr | ₹245.57 Cr | ₹176.45 Cr | ₹100.6 Cr | ₹85.18 Cr | ₹65.96 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹31.69 Cr | ₹6.05 Cr | -₹22.44 Cr | -₹37.72 Cr | -₹58,000 | ₹1.17 Cr | -₹5.04 Cr | -₹6.08 Cr |
| Employee Benefit Expense | ₹32.94 Cr | ₹22.23 Cr | ₹12.5 Cr | ₹11.53 Cr | ₹10.66 Cr | ₹8.66 Cr | ₹8.95 Cr | ₹8.04 Cr |
| Finance Costs | ₹39.3 Cr | ₹22.38 Cr | ₹13.65 Cr | ₹9.28 Cr | ₹4.67 Cr | ₹4.16 Cr | ₹4.41 Cr | ₹3.1 Cr |
| Depreciation & Amortisation | ₹7.91 Cr | ₹4.45 Cr | ₹3.8 Cr | ₹2.81 Cr | ₹2.16 Cr | ₹2 Cr | ₹1.88 Cr | ₹1.33 Cr |
| Other Expenses | ₹62.32 Cr | ₹48.91 Cr | ₹37.69 Cr | ₹27.52 Cr | ₹23.56 Cr | ₹14.33 Cr | ₹9.45 Cr | ₹18.9 Cr |
| Total Expenses | ₹591.54 Cr | ₹428 Cr | ₹327.62 Cr | ₹258.99 Cr | ₹217.49 Cr | ₹130.92 Cr | ₹104.83 Cr | ₹91.24 Cr |
| Profit Before Exceptional Items & Tax | ₹47.58 Cr | ₹28.27 Cr | ₹21.45 Cr | ₹17.51 Cr | ₹8.6 Cr | ₹4.37 Cr | ₹8.46 Cr | ₹6.16 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹1.16 Cr | ₹0 | ₹0 |
| Profit Before Tax | ₹47.58 Cr | ₹28.27 Cr | ₹21.45 Cr | ₹17.51 Cr | ₹8.6 Cr | ₹3.21 Cr | ₹8.46 Cr | ₹6.16 Cr |
| Total Tax Expense | ₹14.38 Cr | ₹7.46 Cr | ₹5.83 Cr | ₹6.7 Cr | ₹2.26 Cr | ₹1.19 Cr | ₹59.27 Lakh | ₹1.7 Cr |
| Net Profit | ₹33.21 Cr | ₹20.81 Cr | ₹15.62 Cr | ₹10.81 Cr | ₹6.34 Cr | ₹2.01 Cr | ₹7.86 Cr | ₹4.46 Cr |
| Other Comprehensive Income | ₹16.55 Lakh | -₹34.35 Lakh | ₹7.04 Lakh | -₹4.92 Lakh | -₹2.25 Lakh | -₹23,000 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹33.37 Cr | ₹20.46 Cr | ₹15.69 Cr | ₹10.76 Cr | ₹6.31 Cr | ₹2.01 Cr | ₹7.86 Cr | ₹4.46 Cr |
| EBITDA (computed) | ₹94.79 Cr | ₹55.1 Cr | ₹38.9 Cr | ₹29.6 Cr | ₹15.43 Cr | ₹10.54 Cr | ₹14.75 Cr | ₹10.59 Cr |
| Basic EPS | ₹68.01 | ₹44.83 | ₹33.66 | ₹22.93 | ₹14.29 | ₹5.05 | ₹4.77 | ₹11.17 |
| Diluted EPS | ₹62.33 | ₹44.83 | ₹33.32 | ₹22.93 | ₹14.29 | ₹5.05 | ₹4.77 | ₹11.17 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹642.14 Cr | ₹486.65 Cr | ₹307.6 Cr | ₹257.28 Cr | ₹186.99 Cr | ₹161.62 Cr | ₹133.16 Cr | ₹104.91 Lakh Cr |
| Non-current Assets | ₹143.89 Cr | ₹59.12 Cr | ₹50.4 Cr | ₹41.07 Cr | ₹34.34 Cr | ₹31.54 Cr | ₹32.05 Cr | ₹32.39 Lakh Cr |
| Current Assets | ₹498.24 Cr | ₹427.53 Cr | ₹257.2 Cr | ₹216.21 Cr | ₹152.65 Cr | ₹130.08 Cr | ₹101.11 Cr | ₹72.52 Lakh Cr |
| Property, Plant & Equipment | ₹117.61 Cr | ₹52.14 Cr | ₹46.15 Cr | ₹38.63 Cr | ₹32.28 Cr | ₹30.32 Cr | ₹30.93 Cr | ₹31.35 Lakh Cr |
| Inventories | ₹269.8 Cr | ₹239.89 Cr | ₹175 Cr | ₹150.12 Cr | ₹46.46 Cr | ₹67.57 Cr | ₹50.46 Cr | ₹40.78 Lakh Cr |
| Trade Receivables | ₹92.69 Cr | ₹177.12 Cr | ₹64.85 Cr | ₹34.56 Cr | ₹90.27 Cr | ₹41.08 Cr | ₹32.79 Cr | ₹17.78 Lakh Cr |
| Cash & Equivalents | ₹64.9 Cr | ₹22.96 Lakh | ₹1.07 Cr | ₹2.95 Cr | ₹1.94 Cr | ₹99.46 Lakh | ₹2.75 Cr | ₹80,927 Cr |
| Equity (Net Worth) | ₹278.71 Cr | ₹141.4 Cr | ₹121.47 Cr | ₹96.38 Cr | ₹68.06 Cr | ₹43.07 Cr | ₹41.32 Cr | ₹38.99 Lakh Cr |
| Equity Share Capital | ₹5.47 Cr | ₹4.72 Cr | ₹4.7 Cr | ₹4.53 Cr | ₹4.43 Cr | ₹3.99 Cr | ₹3.99 Cr | ₹398,963 Cr |
| Borrowings (Non-current) | ₹56.31 Cr | ₹9.61 Cr | ₹5.15 Cr | ₹48.93 Cr | ₹42.04 Cr | ₹29.11 Cr | ₹11.5 Cr | ₹0 |
| Borrowings (Current) | ₹165.72 Cr | ₹156.79 Cr | ₹100.36 Cr | ₹37.6 Cr | ₹10.73 Cr | ₹10.53 Cr | ₹23.41 Cr | ₹0 |
| Total Debt (computed) | ₹222.03 Cr | ₹166.41 Cr | ₹105.51 Cr | ₹86.52 Cr | ₹52.76 Cr | ₹39.64 Cr | ₹34.9 Cr | ₹0 |
| Current Liabilities | ₹296.31 Cr | ₹327.32 Cr | ₹174.47 Cr | ₹106.17 Cr | ₹73.75 Cr | ₹86.46 Cr | ₹77.78 Cr | ₹38.18 Lakh Cr |
| Total Liabilities | ₹363.43 Cr | ₹345.25 Cr | ₹186.13 Cr | ₹160.9 Cr | ₹118.93 Cr | ₹118.55 Cr | ₹91.84 Cr | ₹65.92 Lakh Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹30.81 Cr | -₹28.88 Cr | -₹43.87 Lakh | -₹14.41 Cr | -₹2.38 Cr |
| Investing Cash Flow | -₹73.58 Cr | -₹5.99 Cr | -₹7.64 Cr | -₹9.4 Cr | -₹4.14 Cr |
| Financing Cash Flow | ₹121.82 Cr | ₹38.34 Cr | ₹5.99 Cr | ₹25.18 Cr | ₹7.47 Cr |
| Capital Expenditure | ₹73.58 Cr | ₹5.99 Cr | ₹7.64 Cr | ₹0 | ₹0 |
| Free Cash Flow (computed) | -₹42.77 Cr | -₹34.88 Cr | -₹8.08 Cr | -₹14.41 Cr | -₹2.38 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | ₹79.05 Cr | ₹3.47 Cr | -₹2.08 Cr | ₹1.36 Cr | ₹94.36 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹210.41 Cr | ₹159.93 Cr | ₹143.59 Cr | ₹119.4 Cr | ₹165.44 Cr | ₹101.84 Cr | ₹106.89 Cr | ₹77.54 Cr |
| Other Income | ₹2.64 Cr | ₹99.7 Lakh | ₹1.71 Cr | ₹45.21 Lakh | ₹1.97 Cr | ₹85.58 Lakh | ₹46.16 Lakh | ₹1.28 Cr |
| Total Income | ₹213.05 Cr | ₹160.92 Cr | ₹145.29 Cr | ₹119.86 Cr | ₹167.41 Cr | ₹102.7 Cr | ₹107.35 Cr | ₹78.81 Cr |
| Cost of Materials Consumed | ₹173.54 Cr | ₹118.91 Cr | ₹99.26 Cr | ₹91.08 Cr | ₹125.01 Cr | ₹72.66 Cr | ₹67.4 Cr | ₹57.88 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹22.09 Cr | -₹7.35 Cr | ₹4.41 Cr | -₹6.66 Cr | -₹1.23 Cr | -₹26.07 Lakh | ₹7.87 Cr | -₹32.68 Lakh |
| Employee Benefit Expense | ₹8.86 Cr | ₹8.15 Cr | ₹8.3 Cr | ₹7.63 Cr | ₹9.7 Cr | ₹5.85 Cr | ₹3.58 Cr | ₹3.1 Cr |
| Finance Costs | ₹14.49 Cr | ₹10.55 Cr | ₹7.73 Cr | ₹6.53 Cr | ₹8.15 Cr | ₹5 Cr | ₹5.31 Cr | ₹3.91 Cr |
| Depreciation & Amortisation | ₹3.11 Cr | ₹1.78 Cr | ₹1.6 Cr | ₹1.42 Cr | ₹1.25 Cr | ₹1.09 Cr | ₹1.06 Cr | ₹1.05 Cr |
| Other Expenses | ₹23.61 Cr | ₹14.88 Cr | ₹10.99 Cr | ₹10.81 Cr | ₹16.49 Cr | ₹11.22 Cr | ₹14.55 Cr | ₹7.68 Cr |
| Total Expenses | ₹201.52 Cr | ₹146.92 Cr | ₹132.29 Cr | ₹110.81 Cr | ₹159.37 Cr | ₹95.56 Cr | ₹99.78 Cr | ₹73.29 Cr |
| Profit Before Exceptional Items & Tax | ₹11.53 Cr | ₹14 Cr | ₹13.01 Cr | ₹9.04 Cr | ₹8.04 Cr | ₹7.13 Cr | ₹7.58 Cr | ₹5.52 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹11.53 Cr | ₹14 Cr | ₹13.01 Cr | ₹9.04 Cr | ₹8.04 Cr | ₹7.13 Cr | ₹7.58 Cr | ₹5.52 Cr |
| Total Tax Expense | ₹46.81 Lakh | ₹3.52 Cr | ₹3.27 Cr | ₹2.27 Cr | ₹96.99 Lakh | ₹1.8 Cr | ₹3.3 Cr | ₹1.39 Cr |
| Net Profit | ₹11.07 Cr | ₹10.48 Cr | ₹9.73 Cr | ₹6.77 Cr | ₹7.07 Cr | ₹5.33 Cr | ₹4.27 Cr | ₹4.13 Cr |
| Other Comprehensive Income | ₹16.55 Lakh | ₹0 | ₹0 | ₹0 | -₹34.35 Lakh | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹11.23 Cr | ₹10.48 Cr | ₹9.73 Cr | ₹6.77 Cr | ₹6.73 Cr | ₹5.33 Cr | ₹4.27 Cr | ₹4.13 Cr |
| EBITDA (computed) | ₹29.13 Cr | ₹26.34 Cr | ₹22.34 Cr | ₹16.99 Cr | ₹17.44 Cr | ₹13.23 Cr | ₹13.95 Cr | ₹10.48 Cr |
| Basic EPS | ₹20.22 | ₹19.53 | ₹20.61 | ₹14.33 | ₹14.98 | ₹11.29 | ₹9.05 | ₹8.79 |
| Diluted EPS | ₹18.70 | ₹17.71 | ₹20.61 | ₹14.33 | ₹14.98 | ₹11.29 | ₹9.05 | ₹8.79 |
Charges & Borrowings of Fredun Pharmaceuticals Ltd
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 Oct 2025 | Others | ₹15.45 Lakh | Open |
| 23 Sep 2025 | Axis Bank Limited | ₹24.9 Lakh | Open |
| 23 Sep 2025 | Axis Bank Limited | ₹23.24 Lakh | Open |
| 22 Sep 2025 | Axis Bank Limited | ₹70 Lakh | Open |
| 04 Sep 2025 | Others | ₹2.5 Cr | Open |
Total charge records: 75 View all charges
Employees and EPFO Compliance at Fredun Pharmaceuticals Ltd
View historical data on people associated with Fredun Pharmaceuticals Ltd, including employment history and EPFO contributions.
Employee Count & EPFO Data of Fredun Pharmaceuticals Ltd
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Fredun Pharmaceuticals Ltd
GSTIN & GST Filing Data of Fredun Pharmaceuticals Ltd
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Fredun Pharmaceuticals Ltd
Credit Ratings, Legal Cases & Regulatory Alerts of Fredun Pharmaceuticals Ltd
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Fredun Pharmaceuticals Ltd
MSME Payment Delays by Fredun Pharmaceuticals Ltd
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Fredun Pharmaceuticals Ltd
Subsidiaries & Group Companies of Fredun Pharmaceuticals Ltd
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Fredun Pharmaceuticals Ltd with ownership details.
MCA Filings & Documents of Fredun Pharmaceuticals Ltd
MCA Filings & Documents of Fredun Pharmaceuticals Ltd
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Fredun Pharmaceuticals Ltd
Frequently Asked Questions about Fredun Pharmaceuticals Ltd
Fredun Pharmaceuticals Ltd is an active public limited company in the pharma sector based in Mumbai, Maharashtra, India. It was incorporated on 08 June 1987 (39+ years old) and is registered under CIN L24239MH1987PLC043662. Listed on BSE: 539730. The company has 388 employees.
Fredun Pharmaceuticals Ltd reported revenue of ₹456.27 Cr for FY 2025 (up 31.00% YoY).
The current directors of Fredun Pharmaceuticals Ltd are:
- Fredun Nariman Medhora
- Daisy Dsouza
- Daulat Nariman Medhora
- Anshu Gyan Agarwal
- Sonal Dharmin Desai
- Pooja Narendra Sanghavi
- Vaishnavi Rajkamal Sahu
The primary industry of Fredun Pharmaceuticals Ltd is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Fredun Pharmaceuticals Ltd is listed on BSE with code 539730.
Fredun Pharmaceuticals Ltd can be reached at the registered office: 11Th Floor Tower A Urmi Estate, 95 Ganpatrao Kadam Marg Lower Parel W, Mumbai, Maharashtra, India – 400013, or through the website fredungroup.com.